25-29 October - EVVIVAX to present data at the Veterinary Cancer Society, Portland, Oregon (USA)
Evvivax scientists will be at VCS and present the following abstract:
Tel-eVax™: a Genetic Vaccine targeting Telomerase for treatment of Canine Malignant Lymphoma
Evvivax data shiw that Tel-eVax™ in combination with chemotherapy is safe and immunogenic in canine patients. These data confirm the therapeutic efficacy of dTERT vaccine and hold promise for the treatment of dogs affected by other cancer types. Most importantly, the study outlines the relevance of canine patients as relevant preclinical models for human cancer vaccines.
Tel-eVax targets Telomerase, the enzyme that maintains telomeres and prevents them from shortening during cell division. Telomerase is upregulated in many tumor cells, which enables the continued and uncontrolled proliferation of the malignant cells that drive tumor growth and progression.
Tel-eVax has shown efficacy for canine B-cell Lymphoma in three trials and is currently being evaluated in other tumor types
For more information: